PT - JOURNAL ARTICLE AU - Korodi, Mónika AU - Rákosi, Kinga AU - Jenei, Zsuzsanna AU - Hudák, Gabriella AU - Horváth, István AU - Kákes, Melinda AU - Dallos-Fejér, Katalin AU - Simai, Enikő AU - Staver, Natalia AU - Briciu, Violeta AU - Lupșe, Mihaela AU - Flonta, Mirela AU - Almaș, Ariana AU - Pianoschi, Dana AU - Terza, Livia-Maria AU - Fejer, Szilard N. TI - Longitudinal determination of mRNA-vaccination induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of healthcare workers with and without prior exposure to the novel coronavirus AID - 10.1101/2021.03.17.21253751 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.17.21253751 4099 - http://medrxiv.org/content/early/2021/03/24/2021.03.17.21253751.short 4100 - http://medrxiv.org/content/early/2021/03/24/2021.03.17.21253751.full AB - Background Mass vaccination against the disease caused by the novel coronavirus (COVID-19) is a crucial step in slowing the spread of SARS-CoV-2. The BioNTech/Pfizer (BNT162b2) vaccine has been shown to induce strong immune responses among the vaccinated population. Measuring SARS-CoV-2 anti-spike protein IgG levels is a clinically convenient way to estimate post-vaccination humoral immune responses, but only limited data exists about its short-and long-term dynamics. We present a longitudinal analysis of post-vaccination IgG levels in a cohort of 122 healthcare workers vaccinated with BNT162b2 with weekly follow-up until 35 days past the first dose and results of the first monthly follow-up after that for a subset of these.Methods This prospective, multicenter cohort study consists of two periods for short-term and long-term evaluation of post-vaccination IgG levels. Tests were carried out on 666 samples from 122 participants, using in-house anti-spike 1 and anti-nucleocapsid IgG ELISA assays and a commercial, combined version of these.Findings Participants with previous SARS-CoV-2 infection mount a quick immune response, reaching peak IgG levels two weeks after vaccination. In contrast, the corresponding IgG levels for previously uninfected participants increase gradually, changing abruptly after the booster dose. Overall higher IgG levels are maintained for the previously infected group 35-70 days after vaccination, and we observe age-dependence of immune response as well.Interpretation Our results show a robust humoral immune response mounting gradually after the first vaccine dose for the uninfected group, and a much stronger immune response within 7-14 days after the first dose for the previously infected group.Competing Interest StatementSNF is the CEO of a startup of Pro-Vitam Ltd, and head of the group that developed the combined S1+N ELISA assay, commercialized by the startup.Funding StatementResearch costs were supported by each participating institution. No other funding to disclose.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethics committee of the Hospital for Infectious Diseases Cluj-Napoca, approval no. 756/13.01.2021.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data for each sample (age, gender, day elapsed since the first vaccine dose) and ELISA measurements for SARS-CoV-2 IgG antibodies are available in an Excel spreadsheet. https://szilard.ro/files/covid_antibody_study.xlsx